LivaNova (LIVN), What Is Behind The Fresh Attention?
LivaNova (LIVN) drew fresh attention after raising its 2026 revenue growth guidance to 8% to 9% on a constant currency basis, alongside second quarter results that showed higher sales and net income.
See our latest analysis for LivaNova.
The raised guidance and strong second quarter figures have coincided with a 35.59% year to date share price return and a 53.05% total shareholder return over the past year, suggesting momentum in how the market is viewing LivaNova.
If LivaNova’s move has caught your eye, it can be useful to also look across other medical technology and healthcare AI names using the 42 healthcare AI stocks
After that sharp rerating on stronger guidance and earnings, the real question now is whether most of LivaNova’s upside has already played out, or if the current valuation still leaves meaningful room ahead.
Most Popular Narrative: 3% Undervalued
The most followed narrative currently pegs LivaNova’s fair value at $84.80 compared with a last close of $82.22, which implies a modest discount and frames the current move as relatively measured rather than extreme.
The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.
Want to see what kind of revenue build, margin lift, and future earnings multiple this narrative leans on? The full story connects each assumption to that $84.80 fair value.
Result: Fair Value of $84.80 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, LivaNova’s story can change quickly if reimbursement becomes less supportive or if key neuromodulation and aura6000 adoption trends fall short of expectations.
Find out about the key risks to this LivaNova narrative.
Another View On LivaNova’s Valuation
The SWS DCF model suggests a very different picture for LivaNova. On that view, the stock at $82.22 trades about 40.3% below an estimated future cash flow value of $137.71. That would imply the earlier 3% undervaluation might be too cautious. Which framework do you trust more for your own assumptions?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this mix of optimism and concern around LivaNova feels familiar, it may be useful to move quickly and review the data that matters most to you. A helpful starting point is to compare the company's potential upside with the issues investors are watching through the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond LivaNova?
If LivaNova is on your radar, do not stop there. Broaden your watchlist with other clear opportunities that match your style before they move without you.
- Identify potential value by scanning for companies that appear attractively priced against fundamentals using the 52 high quality undervalued stocks.
- Focus on stability and risk management by reviewing businesses highlighted in the 80 resilient stocks with low risk scores.
- Explore potential standouts that may be overlooked with the screener containing 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com